Mr. Chair, we did invest I believe over $190 million some time ago in this process of attempting to deal with the backlog. I understand that 80% of the backlog has been dealt with. I also understand that this money was invested in 2003 for the next five years in the amount of $190 million.
We are hoping that the drug approval process is shortened, that it is as robust as before if not more so, but shortened so that drugs can be accessed more quickly by Canadians who need them. It is very important that we balance the issue of access with the issue of safety. That is why, if we cannot do it any faster than 300 days for a particular drug, I would seek to be forgiven, because we need to make sure that there is also the balance of safety on the other hand in terms of use by Canadians.